Chemistry:Irampanel
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C18H19N3O2 |
| Molar mass | 309.369 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Irampanel (INN, code name BIIR-561) is a drug which acts as a dual noncompetitive antagonist of the AMPA receptor and neuronal voltage-gated sodium channel blocker.[1][2] It was under development by Boehringer Ingelheim for the treatment of acute stroke/cerebral ischemia but never completed clinical trials for this indication.[3][4] Irampanel was also trialed, originally, for the treatment of epilepsy and pain, but these indications, too, were abandoned,[1] and the drug was ultimately never marketed.
References
- ↑ 1.0 1.1 "Irampanel Boehringer Ingelheim". Current Opinion in Investigational Drugs 3 (6): 908–910. June 2002. PMID 12137411.
- ↑ "Neuroprotection targets after traumatic brain injury". Current Opinion in Neurology 19 (6): 514–519. December 2006. doi:10.1097/WCO.0b013e3280102b10. PMID 17102687. https://zenodo.org/record/895687.
- ↑ "Targeting Molecular Pathways in Stroke". Current Trends in Pharmacology. I. K. International Pvt Ltd. 1 January 2007. pp. 321–. ISBN 978-81-88237-77-7. https://books.google.com/books?id=uB2vWIQBbxoC&pg=PA321.
- ↑ "AMPA receptor antagonists for the treatment of stroke". Current Drug Targets. CNS and Neurological Disorders 4 (2): 153–159. April 2005. doi:10.2174/1568007053544129. PMID 15857300.
| Calcium |
| ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Potassium |
| ||||||||||||||||||||||||
| Sodium |
| ||||||||||||||||||||||||
| Chloride |
| ||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||
| AMPAR |
|
|---|---|
| KAR |
|
| NMDAR |
|
 | 0.00  (0 votes) |
